PT  - JOURNAL ARTICLE
AU  - Shun Adachi
TI  - Novel indicators for evaluating topological threats to populations from pandemics applied to COVID-19
AID  - 10.1101/2020.05.29.20116491
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.29.20116491
4099  - http://medrxiv.org/content/early/2020/10/25/2020.05.29.20116491.short
4100  - http://medrxiv.org/content/early/2020/10/25/2020.05.29.20116491.full
AB  - To deal with pandemics, evaluating the temporal status of an outbreak is important. However, prevailing standards in this respect are mostly empirical and arbitrary. As an alternative, we focus on a novel approach which configures indicators that evaluate topological threats to populations due to the COVID-19 pandemic. We extended the current PzDom model to calculate a threshold of the model for accelerated growth, an indicator of growth extent Re(v), covariance Re(s), a topological number E(l), and expected sums of possibly increasing numbers of infected people. We term this the exPzDom model. The indicators in the exPzDom model adhere well to the empirical dynamics of SARS-CoV-2 infected people and align appropriately with actual policies instituted by the Japanese government. The described indicators could be leveraged pursuant of objective evaluation based on mathematics. Further testing of the reliability and robustness of exPzDom model in other pandemic contexts is warranted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding for this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB/oversight body is exempted.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data and a code for the analyses are available via indicated links. https://github.com/kaz-ogiwara/covid19 https://github.com/CSSEGISandData/COVID-19 https://github.com/sadachi79/exPzDom